Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Peginterferon alfa-2b and ribavirin for treatment-refractory chronic hepatitis C.

Journal of hepatology - 1 Aug 2005

Krawitt Edward L, Ashikaga Takamaru, Gordon Stuart R, Ferrentino Nicholas, Ray Mary Ann, Lidofsky Steven D

Abstract excerpt

BACKGROUND/AIMS: Treatment regimens with pegylated interferons have yielded improved response rates, compared with conventional interferon-based regimens, for chronic hepatitis C. However, little is known about the utility of such regimens for individuals who failed to respond to prior conventional interferon-based treatment. METHODS: 182 patients who had previously failed to eliminate circulating hepatitis C...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to Drug Resistance, Viral

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Therapy, Combination

Share to Hepatitis C, Chronic

Share to Interferon-alpha

Share to Interferon alpha-2

Share to Polyethylene Glycols

Share to Ribavirin

Source

Identifiers

PMID: 16082735
DOI: 10.1016/j.jhep.2005.03.015

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Peginterferon alfa-2b and ribavirin for treatment-refractory chronic hepatitis C.PMID 16082735Read ↗

Relapse to prior therapy is the most important factor for the retreatment response in patients with chronic hepatitis C virus infection.Semantic proximity Read ↗

Re-treatment with peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have relapsed or not responded to a first course of pegylated interferon-based therapy.Semantic proximity Read ↗

Treatment options for nonresponders and relapsers to initial therapy for hepatitis C.Semantic proximity Read ↗

A randomized trial of pegylated interferon alpha-2b plus ribavirin in the retreatment of chronic hepatitis C.Semantic proximity Read ↗

The effectiveness of retreatment with peginterferon alfa and ribavirin in patients with chronic viral hepatitis C genotype 2 and 3: a prospective cohort study in Brazil.Semantic proximity Read ↗

Management of patients with chronic hepatitis C virus infection and previous nonresponse.Semantic proximity Read ↗

Retreatment of patients with chronic hepatitis C relapsers to a previous antiviral treatment.Semantic proximity Read ↗

Retreatment of patients who do not respond to initial therapy for chronic hepatitis C.Semantic proximity Read ↗

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.Semantic proximity Read ↗

Efficacy of interferon alpha-2b induction therapy before retreatment for chronic hepatitis C.Semantic proximity Read ↗

Retreatment with peg-interferon and ribavirin in patients with chronic hepatitis C virus genotype 2 or 3 infection with prior relapse.Semantic proximity Read ↗

Interferon-alpha plus ribavirin for 12 months increases the sustained response rates in chronic hepatitis C relapsers.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.